This old drug can save your life from COVID-19

Knowridge Science Report
Knowridge Science Report
Credit: CC0 Public Domain

In a new study from McMaster University, researchers found an inexpensive repurposed drug called fluvoxamine can save the lives of COVID-19 patients and cut hospital admissions by up to 30%.

The treated 739 Brazilian COVID-19 patients with fluvoxamine, with another 733 receiving a placebo, between Jan. 15 to Aug. 6 of this year.

Every patient who received fluvoxamine during the trial was tracked for 28 days to determine their health outcomes and if they still need hospital treatment.

Researchers found about a 30% reduction in hospitalizations among those receiving fluvoxamine compared to those receiving the placebo.

This effect went up to 65% among patients taking all of their drugs. The fluvoxamine trial formed part of the larger TOGETHER Trial that started in May 2020, aiming to test potential COVID-19 treatments in a community setting.

The team says fluvoxamine is the only treatment that if administered early, can prevent COVID-19 from becoming a life-threatening illness.

It could be one of our most powerful weapons against the virus and its effectiveness is one of the most important discoveries researchers have made since the pandemic began

In addition, this cheap, easily-accessible pill is a massive boon to public health, both in Canada and internationally, allowing hospitals to avoid expensive and sometimes risky treatments.

Costing about $4 per 10-day course, fluvoxamine could be a game-changer for poorer countries with low vaccination rates and lacking access to more advanced COVID-19 therapies.

Fluvoxamine has been used since the 1990s for various conditions and its safety profile is well-known. It was identified early in the pandemic for its potential to reduce the cytokine storm in COVID-19 patients.

Cytokine storms are severe immune responses to COVID-19 that can cause potentially lethal organ damage.

If you care about COVID, please read studies about this drug can block multiple COVID-19 variants and findings of this stuff adds fuel to COVID-19 inflammation.

For more information about COVID and your health, please see recent studies about the nose shows why some people get severe COVID-19 and results about why are we seeing more COVID cases in fully vaccinated people?

The study is published in The Lancet. One author of the study is Edward Mills.

Copyright © 2021 Knowridge Science Report. All rights reserved.

Comments / 38

Humanity is Broken

I’ve taken fluvoxamine for decades. It was originally sold under the brand name Luvox with fluvoxamine being the generic name. When it was approved for generic sales it was so inexpensive that they stopped producing it under the brand name. I take it for depression and OCD. It’s an SSRI so it messes with your brain chemistry. I don’t know if people really want to take an antidepressant if it’s not necessary.

Frank Quintana

why haven't American doctors interested in medications that are ready available to treat the CCP virus, because there's no money in it, so they're not interested, and don't care to do the research. They rely on big money therapeutics, making money off gov., free money, there is NOTHING free.


Bingo. I take Plaquenil for Lupus. It used to be easily available. Now the federal government has re-classed the drug so your insurance has to approve it first. They asked my physician Why I need it. Pretty Big Red Flag it works!!!


Comments / 0